Methods for tracking radiolabeled liposomes after injection in the body

Liposome Technology: Interactions of Liposomes with the Biological Milieu

Volumn , Issue , 2006, Pages 191-210

  Goins, Beth A ^a   Phillips, William T ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84881711424     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (62)

1. Boerman OC, Laverman P, Oyen WJ, et al. Radiolabeled liposomes for scintigraphic imaging. Prog Lipid Res 2000; 39(5):461-475.
2. Boerman OC, Rennen H, Oyen WJ, et al. Radiopharmaceuticals to image infection and inflammation. Semin Nucl Med 2001; 31(4):286-295.
3. Goins B, Phillips WT. Radiolabelled liposomes for imaging and bio distribution studies. In: Torchilin VP, Weissig V, eds. Liposomes A Practical Approach. 2nd ed. Oxford, U.K.: Oxford University Press, 2003:319-336.
4. Goins BA, Phillips WT. The use of scintigraphic imaging as a tool in the development of liposome formulations. Prog Lipid Res 2001; 40(1-2):95-123.
5. Laverman P, Boerman OC, Storm G. Radiolabeling of liposomes for scintigraphic imaging. Meth Enzymol 2003; 373:234-248.
6. Phillips WT, Goins B. Assessment of liposome delivery using scintigraphic imaging. J Liposome Res 2002; 12(1-2):71-80.
7. Tilcock C. Delivery of contrast agents for magnetic resonance imaging, computed tomography, nuclear medicine and ultrasound. Adv Drug Deliv Rev 1999; 37(1-3):33-51.
8. Torchilin VP. Polymeric contrast agents for medical imaging. Curr Pharm Biotechnol 2000; 1(2):183-215.
9. Blankenberg FG, Strauss HW. Nuclear medicine applications in molecular imaging. J Magn Reson Imaging 2002; 16(4):352-361.
10. Wolf GL. Targeted delivery of imaging agents: an overview. In: Torchilin VP, ed. Handbook of Targeted Delivery of Imaging Agents. Boca Raton, FL:CRC Press, 1995:3-22.
11. Blasberg R. Imaging gene expression and endogenous molecular processes:molecular imaging. J Cereb Blood Flow Metab 2002; 22(10):1157-1164.
12. Hargreaves R. Imaging substance P receptors (NK1) in the living human brain using positron emission tomography. J Clin Psychiatry 2002; 63(suppl 11):18-24.
13. Phelps ME. PET: the merging of biology and imaging into molecular imaging. J Nucl Med 2000; 41(4):661-681.
14. Ray P, Bauer E, Iyer M, et al. Monitoring gene therapy with reporter gene imaging. Semin Nucl Med 2001; 31:312-320.
15. Sharma V, Luker GD, Piwnica-Worms D. Molecular imaging of gene expression and protein function in vivo with PET and SPECT. J Magn Reson Imaging 2002; 16(4):336-351.
16. Van de Wiele C, Lahorte C, Oyen W, et al. Nuclear medicine imaging to predict response to radiotherapy: a review. Int J Radiat Oncol Biol Phys 2003; 55(1):5-15.
17. Winnard P Jr., Raman V. Real time non-invasive imaging of receptor-ligand interactions in vivo. J Cell Biochem 2003; 90(3):454-463.
18. Awasthi V, Goins B, Klipper R, et al. Imaging experimental osteomyelitis using radiolabeled liposomes. J Nucl Med 1998; 39(6):1089-1094.
19. Awasthi VD, Goins B, Klipper R, et al. Dual radiolabeled liposomes: biodistribution studies and localization of focal sites of infection in rats. Nucl Med Biol 1998; 25(2):155-160.
20. Marsee DK, Shen DH, MacDonald LR, et al. Imaging of metastatic pulmonary tumors following NIS gene transfer using single photon emission computed tomography. Cancer Gene Ther 2004; 11(2):121-127.
21. Perkins AC, Frier M. Radionuclide imaging in drug development. Curr Pharm Des 2004; 10(24):2907-2921.
22. Graham LS, Muehllehner G. Anger Scintillation Camera. In: Sandler MP, ed. Diagnostic Nuclear Medicine. Baltimore: Williams & Wilkins, 1996:81-92.
23. Bocher M, Balan A, Krausz Y, et al. Gamma camera-mounted anatomical X-ray tomography: technology, system characteristics and first images. Eur J Nucl Med 2000; 27(6):619-627.
24. Humm JL, Rosenfeld A, Del Guerra A. From PET detectors to PET scanners. Eur J Nucl Med Mol Imaging 2003; 30(11):1574-1597.
25. Keidar Z, Israel O, Krausz Y. SPECT/CT in tumor imaging: technical aspects and clinical applications. Semin Nucl Med 2003; 33(3):205-218.
26. Phelps ME, Cherry SR. The changing design of positron imaging systems. Clin Positron Imaging 1998; 1(1):31-45.
27. Acton PD, Kung HF. Small animal imaging with high resolution single photon emission tomography. Nucl Med Biol 2003; 30(8):889-895.
28. Galt JR, Faber T. Principles of single photon emission computed tomography (SPECT) imaging. In: Christian PE, Bernier DR, Langan JK, eds. Nuclear Medicine and PET: Technology and Techniques. 5th ed. St. Louis, MO: Mosby, 2004:242-284.
29. Koukourakis MI, Koukouraki S, Giatromanolaki A, et al. Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small-cell lung cancer and head and neck cancer. J Clin Oncol 1999; 17(11):3512-3521.
30. Harrington KJ, Mohammadtaghi S, Uster PS, et al. Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin Cancer Res 2001; 7(2):243-254.
31. Green MV, Seidel J, Vaquero JJ, et al. High resolution PET, SPECT and projection imaging in small animals. Comput Med Imaging Graph 2001; 25(2):79-86.
32. Lewis JS, Achilefu S, Garbow JR, et al. Small animal imaging: current technology and perspectives for oncological imaging. Eur J Cancer 2002; 38(16):2173-2188.
33. Herschman HR. Molecular imaging: looking at problems, seeing solutions. Science 2003; 302(5645):605-608.
34. Hildebrandt IJ, Gambhir SS. Molecular imaging applications for immunology. Clin Immunol 2004; 111(2):210-224.
35. Lyons SK. Advances in imaging mouse tumour models in vivo. J Pathol 2005; 205(2):194-205.
36. Del Guerra A, Belcari N. Advances in animal PET scanners. Q J Nucl Med 2002; 46(1):35-47.
37. Ritman EL. Molecular imaging in small animals-roles for micro-CT. J Cell Biochem Suppl 2002; 39:116-124.
38. Ritman EL. Micro-computed tomography-current status and developments. Annu Rev Biomed Eng 2004; 6:185-208.
39. Cherry SR, Phelps ME. Positron emission tomography: methods and instrumentation. In: Sandler MP, ed. Diagnostic Nuclear Medicine. Baltimore: Williams & Wilkins, 1996:139-159.
40. Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology. Radiology 2004; 231(2):305-332.
41. Couturier O, Luxen A, Chatal JF, et al. Fluorinated tracers for imaging cancer with positron emission tomography. Eur J Nucl Med Mol Imaging 2004; 31(8):1182-1206.
42. Delbeke D, Martin WH. Metabolic imaging with FDG: a primer. Cancer J 2004; 10(4):201-213.
43. Avril NE, Weber WA. Monitoring response to treatment in patients utilizing PET. Radiol Clin North Am 2005; 43(1):189-204.
44. Dutour A, Monteil J, Paraf F, et al. Endostatin cDNA/cationic liposome complexes as a promising therapy to prevent lung metastases in osteosarcoma: study in a human-like rat orthotopic tumor. Mol Ther 2005; 11(2):311-319.
45. Iyer M, Berenji M, Templeton NS, et al. Noninvasive imaging of cationic lipidmediated delivery of optical and PET reporter genes in living mice. Mol Ther 2002; 6(4):555-562.
46. Beyer T, Townsend DW, Blodgett TM. Dual-modality PET/CT tomography for clinical oncology. Q J Nucl Med 2002; 46(1):24-34.
47. Fahey FH. Instrumentation in positron emission tomography. Neuroimaging Clin N Am 2003; 13(4):659-669.
48. Robinson MK, Doss M, Shaller C, et al. Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody. Cancer Res 2005; 65(4):1471-1478.
49. Kondo M, Asai T, Katanasaka Y, et al. Anti-neovascular therapy by liposomal drug targeted to membrane type-1 matrix metalloproteinase. Int J Cancer 2004; 108(2):301-306.
50. Oku N. Delivery of contrast agents for positron emission tomography imaging by liposomes. Adv Drug Deliv Rev 1999; 37(1-3):53-61.
51. Oku N, Namba Y. Glucuronate-modified, long-circulating liposomes for the delivery of anticancer agents. Meth Enzymol 2005; 391:145-162.
52. Wu AM, Yazaki PJ, Tsai S, et al. High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment. Proc Natl Acad Sci USA 2000; 97(15):8495-8500.
53. Wipke BT, Wang Z, Kim J, et al. Dynamic visualization of a joint-specific autoimmune response through positron emission tomography. Nat Immunol 2002; 3(4):366-372.
54. Goins B, Klipper R, Martin C, et al. Use of oxygen-15-labeled molecular oxygen for oxygen delivery studies of blood and blood substitutes. Adv Exp Med Biol 1998; 454:643-652.
55. Phillips WT, Lemen L, Goins B, et al. Use of oxygen-15 to measure oxygencarrying capacity of blood substitutes in vivo. Am J Physiol 1997; 272(5 Pt 2):H2492-H2499.
56. Rudolph AS, Klipper RW, Goins B, et al. In vivo biodistribution of a radiolabeled blood substitute: 99mTc-labeled liposome-encapsulated hemoglobin in an anesthetized rabbit. Proc Natl Acad Sci USA 1991; 88(23):10976-10980.
57. Goins B, Klipper R, Rudolph AS, et al. Use of technetium-99m-liposomes in tumor imaging. J Nucl Med 1994; 35(9):1491-1498.
58. Matteucci ML, Anyarambhatla G, Rosner G, et al. Hyperthermia increases accumulation of technetium-99m-labeled liposomes in feline sarcomas. Clin Cancer Res 2000; 6(9):3748-3755.
59. Boerman OC, Oyen WJ, Storm G, et al. Technetium-99m labelled liposomes to image experimental arthritis. Ann Rheum Dis 1997; 56(6):369-373.
60. Goins B, Klipper R, Rudolph AS, et al. Biodistribution and imaging studies of technetium-99m-labeled liposomes in rats with focal infection. J Nucl Med 1993; 34(12):2160-2168.
61. Harrington KJ. Liposomal cancer chemotherapy: current clinical applications and future prospects. Expert Opin Investig Drugs 2001; 10(6):1045-1061.
62. Frank DW. Physiological data of laboratory animals. In: Melby ECJ, ed. Handbook of Laboratory Animal Science. Boca Raton, FL: CRC Press, 1976:23-64.